Blocking of Glucagonlike Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity for β-Cells in a Mouse Model of Type 1 Diabetes
- 10 May 2019
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 60 (11), 1635-1641
- https://doi.org/10.2967/jnumed.118.224881
Abstract
The diabetes community has long desired an imaging agent to quantify the number of insulin-secreting beta (β) cells, beyond just functional equivalents (insulin secretion), to help diagnose and monitor early stages of both type 1 and type 2 diabetes mellitus. Loss in the number of β-cells can be masked by a compensatory increase in function of the remaining cells. Since β-cells only form ~1% of the pancreas and decrease as the disease progresses, only a few imaging agents, such as exendin, have demonstrated clinical potential to detect a drop in the already scarce signal. However, clinical translation of imaging with exendin has been hampered by higher than expected pancreatic uptake in subjects with long-term diabetes who lack β-cells. Exendin binds glucagon-like peptide 1 receptor (GLP-1R), previously thought to be expressed only on β-cells, but recent studies report low levels of GLP-1R on exocrine cells, complicating β-cell mass quantification. Here we use a GLP-1R knockout mouse model to demonstrate that exocrine binding of exendin is exclusively via GLP-1R (~1,000/cell), and not any other receptors. We then use lipophilic Cy-7 exendin to selectively pre-block exocrine GLP-1R in healthy and streptozotocin-induced diabetic (STZ) mice. Sufficient receptors remain on β-cells for subsequent labeling with a fluorescent- or 111In-exendin, which improves contrast between healthy and diabetic pancreata, and provides a potential avenue for achieving the long-standing goal of imaging β-cell mass in the clinic.Keywords
This publication has 37 references indexed in Scilit:
- Attempted suicide with liraglutide overdose did not induce hypoglycemiaDiabetes Research and Clinical Practice, 2012
- Differential Effects of Predosing on Tumor and Tissue Uptake of an111In-Labeled Anti-TENB2 Antibody–Drug ConjugateJournal of Nuclear Medicine, 2012
- Value of the radiolabelled GLP-1 receptor antagonist exendin(9–39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humansEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- High-throughput 3D spheroid culture and drug testing using a 384 hanging drop arrayThe Analyst, 2010
- Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypassDiabetologia, 2010
- Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression LevelsMolecular Imaging & Biology, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- Islet architecture: A comparative studyIslets, 2009
- GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo TargetingJournal of Nuclear Medicine, 2007
- Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor geneNature Medicine, 1996